Medical and Surgical Prevention of Stroke: Experiences around the World

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 22-28

  Busch, M ^a   Masuhr, F ^a   Einhaupl F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Anticoagulation; Antiplatelet agents; Aspirin; Atrial fibrillation; Carotid endarterectomy; Carotid stenosis; Clinical trials; Stroke prevention; Ticlopidine; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CONFERENCE PAPER; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; STROKE;

EID: 0031028840     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108233     Document Type: Article

References (45)

1. Caplan LR (ed): Koudstaai PJ, Barnett HJM, Adams HP, Bendixen BH, Jacoby MR: How should clinicians choose treatment for preventing stroke when therapeutic trials arc not available to guide the situation? Eur Neurol 1995; 35:293-308.
2. Van Gijn J: Extrapolation of trials data into practice: Where is the limit? Cerebrovasc Dis 1995;5:159-162.
3. Fields WS, Lemak NA, Frankowski RF, Hardy RJ: Controlled trial of aspirin in cerebral ischemia. Stroke 1977;8:301-316.
4. Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978:299:53-59.
5. Guiraud-Chaumeuil B, Rascol A, David JL, Boneu B, Clanet M, Bienne R: Prevention des récidives des accidentes vasculaires cérébraux ischémiques par les anti-agrégants plaqucttai-rcs: résultats d'un essai thérapeutique contrôlé de 3 ans. Rev Neurol (Paris) 1982:138:367— 385.
6. Bousser MG, Eschwegc E, Hagucnau M. et al: ‘AICLA’ controlled trial of apsirin and dipyridamole in the secondary prevention of alhcro-thrombotic cerebral ischemia. Stroke 1983:14: 5-14.
7. Sorensen PS, Pedersen H, Marquardscn J. ct al: Acetylsalicylic acid in the prevention of stroke in patients with reversible cerebral ischemic attacks: a Danish Cooperative Studv. Stroke 1983:14:15-22.
8. Britton M, Helmers C, Samuelsson K: Higli-dosc acetylsalicylic acid after cerebral infarction: A Swedish Cooperative Study. Stroke 1987;18:325-334.
9. UK-TIA Study Group: The United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Ncurosurg Psychiatry 1991:54:1044-1054.
10. The SALT Collaborative Group: Swedish Aspirin Low-dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis alter cerebrovascular ischaemic events. Lancet 1991;338:1345— 1349.
11. The Dutch T1A Trial Study Group: A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991:325:1261-1266.
12. Antiplatelet Trialists’ Collaboration: Collaborative overview of randomised trials of anti-platelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged an-tiplatclet therapy in various categories of patients. BMJ 1994;308:81-106.
13. Dykcn ML, Barnett HJM, Easton JD, Fields WS, Fustcr V, Hachinski V, Norris JW, Sherman DG: Low-dose aspirin and stroke: it ain't necessarily so.' Stroke 1992:23:1395-1399.
14. Algra A, Van Gijn J: Apsirin al any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Ncurosurg Psychiatry 1996:60:197-199.
15. Hart RG, Harrison MJG: Aspirin wars. The optimal dose of aspirin to prevent stroke. Stroke 1996:27:585-587.
16. Barnett HJM, Kaste M, Mcldrum II, Eliasziw M: Aspirin dose in stroke prevention: Beautiful hypotheses slain by ugly facts. Stroke 1996:27: 588-592.
17. Gent M, Blakely JA, Easton JD. et al: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989:1: 1215-1220.
18. Hass WK, Easton JD, Adams HP Jr. et al: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevcniion of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
19. The Amcrican-Canadian Co-Operative Study Group: Persantine aspirin trial in cerebral ischemia: endpoint results. Stroke 1985:16:406 - 415.
20. Acheson J, Danta G, Hutchinson EC: Controlled trial of dipyridamole in cerebral vascular disease. BMJ 1969:1:614-615.
21. Gent M, Blakeley JA, Hachinski V: A secondary' prevention, randomized trial of suloctidil in patients with a recent history of thromboembolic stroke. Stroke 1985:16:416-424.
22. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet 1989;1:175—179.
23. Boston Area Anticoagulation Trial in Atrial Fibrillation Investigators: The effect of low dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med 1990:323:1505-1511.
24. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. and CAFA Study Coin-vestigators: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Ain Coll Cardiol 1991:18:349-355.
25. Stroke Prevention in Atrial Fibrillation Investigators: The Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991: 84:527-539.
26. Ezckowitz MD, Bridgers SL, James KE. et al. for the Veterans Affairs SPINAF Investigators: Warfarin in the prevention of stroke associated with non-rheumatic atrial fibrillation. N Engl J Med 1992:327:1406-1412.
27. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993:342: 1255-1262.
28. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994:343:687-691.
29. Hirsh J, Fustcr V: Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Amercian Heart Association. Circulation 1994:89:1469 - 1480.
30. European Carotid Surgery Trialists Collaborative Group: MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carol id stenosis. Lancet 1991:377:1235-1243.
31. North American Symptomatic Carotid Endar-terectomy Trial Collaborators: Beneficial effect of carotid cndartcrcctomy in symptomatic patients with high-grade stenosis. N Engl J Med 1991:325:445-453.
32. Executive Commitee For The Asymptomatic Carotid Atherosclerosis Study Group: Endar-lercctomy for asymptomatic carotid artery stenosis. JAMA 1995:273:1421-1428.
33. Mayberg MR. Winn HR: Endartercctomy for asymptomatic carotid artery stenosis (editorial). JAMA 1995:273:1459-1461.
34. Frey JL: Asymptomatic Carotid Surgery: Surgery's the answer, but that’s not the question. Ann Neurol 1996;39:405-406.
35. Barnett HJ, Eliasziw M, Meldrum HE, Taylor DW: Do the facts and figures warrant a 10-fold increase in the performance of carotid endar-tercctomy on asymptomatic patients? Neurology 1996:46:603-608.
36. Goldstein LB, Bonito AJ, Matchar DB, Duncan PW, DcFricsc GH. Oddonc EZ, Paul JE, Akin DR, Samsa GP: US National survey of physician practice for the secondary and tertiary prevention of ischemic stroke. Stroke 1995: 26:1607-1615.
37. Helgason CM, Bolin KM, Hoff JA, Winkler SR. Mangat A, Tortoricc K.L, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994:25: 2331-2336.
38. Patrono C, Roth GJ: Aspirin in ischemic cerebrovascular disease: How strong is the case for a different dosing regimen? Stroke 1996:27: 756-760.
39. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern med 1994;154:1449-1457.
40. Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994:154:1443-1448.
41. The European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995;333:5-10.
42. Henncrici M, Hiilsbömcr H-B, Hefter H, Lam-merts D, Rautenberg W: Natural history of asymptomatic extracrania! arterial disease. Results of a long-term prospective study. Brain 1987;110:77-791.
43. Norris JW, Zhu CZ. Bomstein NM, Chambers ÜR: Vascular risks of asymptomatic carotid stenosis. Stroke 1991;22:1485-1490.
44. Rothwell PM, Slattery J, Warlow CP: Risk of stroke in the distribution of an asymptomatic carotid artery. Lancet 1995;345:209-212.
45. Halliday AW, Thomas D, Mansfield A: The asymptomatic surgery trial (ACST) rationale and design. EurJ VascSurg 1994:8:703-710.